Auris Story

<div class='circular--portrait' style='background:#4E8BFC;color: #ffffff;font-size:4em;'>AM</div>
EARS -- USA Stock  

USD 3.25  0.02  0.61%

The stock is currently experiencing an active upward rally. Auris Medical Debt to Equity Ratio is relatively stable at the moment as compared to the past year. Auris Medical reported last year Debt to Equity Ratio of 0.48. As of 01/23/2021, Enterprise Value over EBITDA is likely to grow to 0.16, while Earnings before Tax are likely to drop (6.6 M). As many baby boomers are still indifferent towards healthcare space, it makes sense to sum up Auris Medical Holding as a unique choice for millenniums.
Published over a month ago
View all stories for Auris Medical | View All Stories
Will Auris (NASDAQ:EARS) stockholders stop to drop in February?
This firm currently holds 2.16 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. The company has a current ratio of 0.16, indicating that it has a negative working capital and may not be able to pay financial obligations when due.
Auris Medical financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Auris Medical, including all of Auris Medical's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Auris Medical assets, the company is considered highly leveraged. Understanding the composition and structure of overall Auris Medical debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it.
Please read more on our technical analysis page.

Understanding Auris Total Liabilities

Auris Medical liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. Auris Medical has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on Auris Medical balance sheet include debt obligations and money owed to different Auris Medical vendors, workers, and loan providers. Below is the chart of Auris short long-term liabilities accounts currently reported on its balance sheet.
You can use Auris Medical financial leverage analysis tool to get a better grip on understanding its financial position

How important is Auris Medical's Liquidity

Auris Medical financial leverage refers to using borrowed capital as a funding source to finance Auris Medical ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Auris Medical financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Auris Medical's total debt and its cash.

Another Deeper Perspective

Net Loss for the year was (12.5 M) with profit before overhead, payroll, taxes, and interest of 0.

Liabilities Breakdown

Tax Liabilities
2.1 M
Current Liabilities
1.1 M
Long-Term Liabilities
Total Liabilities2.95 Million
Current Liabilities2.1 Million
Long-Term Liabilities1.08 Million
Tax Liabilities182,737

Over 3 percent spike for Auris Medical. What does it mean for retail investors?

Variance is down to 2134.49. It may connote a possible volatility fall. Auris Medical Holding is displaying above-average volatility over the selected time horizon. Investors should scrutinize Auris Medical Holding independently to ensure intended market timing strategies are aligned with expectations about Auris Medical volatility.

Our Conclusion on Auris Medical

While some companies within the biotechnology industry are still a little expensive, even after the recent corrections, Auris Medical may offer a potential longer-term growth to retail investors. The inconsistency in the assessment between current Auris valuation and our trade advice on Auris Medical is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Auris Medical.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Auris Medical. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com